Scynexis (SCYX) Income from Non-Controlling Interests (2014)
Scynexis' (SCYX) quarterly Income from Non-Controlling Interests came in at -$7.3 million in Q2 2014, down 162.2% quarter-over-quarter from -$2.8 million in Q1 2014.
Powered by 
Analysis
Scynexis (SCYX) Income from Non-Controlling Interests (2014) Analysis & Trends
Scynexis (SCYX) has reported Income from Non-Controlling Interests for 1 consecutive years, with -$7.3 million the latest figure, recorded in Q2 2014.
- For the quarter ending Q2 2014, Income from Non-Controlling Interests changed N/A year-over-year to -$7.3 million; the trailing twelve-month figure through Mar 2015 stood at -$7.3 million (changed N/A YoY), and the FY2025 full-year result was $280000.0, up 12.45% from the prior year.
- Income from Non-Controlling Interests slipped to -$7.3 million in Q2 2014 per SCYX's latest filing, from -$2.8 million in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at -$2.8 million in Q1 2014 and bottomed at -$7.3 million in Q2 2014.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -100.77 Mn |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - | - |